Search research articles
Contact Us
Filters
Showing results (131-140 of 148) with videos related to
Page
of 15
Sort By:
Cancer Immunology, Immunotherapy : CII
|
January 1, 1988
Long-term influence of adjuvant therapy on natural killer cell activity in breast cancer
E Tichatschek, C C Zielinski, C Müller, et al.
Gynecologic Oncology
|
December 1, 1995
DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer
M Medl, P Sevelda, K Czerwenka, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1992
Adjuvant tamoxifen in postmenopausal patients with breast cancer and negative axillary lymph nodes
C Scholten, P Sevelda, C Kurz, et al.
Geburtshilfe Und Frauenheilkunde
|
November 1, 1985
[Results of the first Austrian multicenter ovarian cancer study: prospective randomized comparison of sequential chemotherapy (adriamycin/cisplatin--vincristine/cyclophosphamide--methotrexate) with 2 standard protocols (adriamycin/cyclophosphamide or adriamycin/cisplatin) in stage III and IV patients]
H Salzer, E Gitsch, C Dittrich, et al.
British Journal of Cancer
|
March 1, 1994
A comparative analysis of management and prognosis in stage I and II fallopian tube carcinoma and epithelial ovarian cancer
A C Rosen, P Sevelda, M Klein, et al.
Anticancer Research
|
September 1, 1995
The influence of obesity on the disease-free survival in primary breast cancer
A Obermair, C Kurz, E Hanzal, et al.
Onkologie
|
October 1, 1987
[Effect of hormone receptors on the site of metastases in breast cancer]
I Stuller, C C Zielinski, P Aiginger, et al.
British Journal of Cancer
|
July 1, 1992
Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group
C Seynaeve, J Schuller, K Buser, et al.
Geburtshilfe Und Frauenheilkunde
|
January 1, 1996
[Plasminogen activator inhibitor 1 and prognosis in breast carcinoma]
K Mayerhofer, J Stolzlechner, S Yildiz, et al.
Oncology Reports
|
April 18, 2000
Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer
A Obermair, E Petru, G Windbichler, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 148) with videos related to
Sort By:
Page
of 15
Cancer Immunology, Immunotherapy : CII
|
January 1, 1988
Long-term influence of adjuvant therapy on natural killer cell activity in breast cancer
E Tichatschek, C C Zielinski, C Müller, et al.
Gynecologic Oncology
|
December 1, 1995
DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer
M Medl, P Sevelda, K Czerwenka, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1992
Adjuvant tamoxifen in postmenopausal patients with breast cancer and negative axillary lymph nodes
C Scholten, P Sevelda, C Kurz, et al.
Geburtshilfe Und Frauenheilkunde
|
November 1, 1985
[Results of the first Austrian multicenter ovarian cancer study: prospective randomized comparison of sequential chemotherapy (adriamycin/cisplatin--vincristine/cyclophosphamide--methotrexate) with 2 standard protocols (adriamycin/cyclophosphamide or adriamycin/cisplatin) in stage III and IV patients]
H Salzer, E Gitsch, C Dittrich, et al.
British Journal of Cancer
|
March 1, 1994
A comparative analysis of management and prognosis in stage I and II fallopian tube carcinoma and epithelial ovarian cancer
A C Rosen, P Sevelda, M Klein, et al.
Anticancer Research
|
September 1, 1995
The influence of obesity on the disease-free survival in primary breast cancer
A Obermair, C Kurz, E Hanzal, et al.
Onkologie
|
October 1, 1987
[Effect of hormone receptors on the site of metastases in breast cancer]
I Stuller, C C Zielinski, P Aiginger, et al.
British Journal of Cancer
|
July 1, 1992
Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group
C Seynaeve, J Schuller, K Buser, et al.
Geburtshilfe Und Frauenheilkunde
|
January 1, 1996
[Plasminogen activator inhibitor 1 and prognosis in breast carcinoma]
K Mayerhofer, J Stolzlechner, S Yildiz, et al.
Oncology Reports
|
April 18, 2000
Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer
A Obermair, E Petru, G Windbichler, et al.
Page
of 15